Ariella Bar-Gil Shitrit1, Ami Ben-Ya'acov1, Matan Siterman2, Matti Waterman3, Ayal Hirsh4, Doron Schwartz5, Eran Zittan6, Yehonatan Adler7, Benjamin Koslowsky1, Irit Avni-Biron2, Yehuda Chowers3, Yulia Ron4, Eran Israeli8, Bella Ungar7, Henit Yanai2, Nitsan Maharshak4, Shomron Ben-Horin7, Rami Eliakim7, Iris Dotan2, Eran Goldin1, Uri Kopylov7. 1. Digestive Diseases Institute, Shaare Zedek Medical Center, affiliated with Faculty of Medicine, The Hebrew University, Jerusalem, Israel. 2. Division of Gastroenterology, Rabin Medical Center, Petah Tikva, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel. 4. Inflammatory Bowel Disease Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 5. Department of Gastroenterology, Soroka Medical Center, Beer Sheva, Israel. 6. Inflammatory Bowel Disease Unit, Ellen and Pinchas Mamber Institute of Gastroenterology and Liver Diseases, Emek Medical Center, Afula, Israel. 7. Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel. 8. Institute of Gastroenterology, Hebrew University Hadassah Medical Center, Jerusalem, Israel.
Abstract
INTRODUCTION: Ustekinumab is an effective treatment of Crohn's disease (CD). Real-world data addressing the efficacy and safety of ustekinumab are scarce. AIM: Our aim was to assess the safety and efficacy of ustekinumab in a large national patient cohort. METHODS: A prospective multicenter study, in which we followed patients with active CD treated with ustekinumab for 24 weeks. Induction dose was intravenous ranging from 260 to 520 mg, according to body weight, followed by 90 mg doses given subcutaneously every 8 weeks. Clinical response was defined as a reduction of at least 1 severity category, as defined by Harvey-Bradshaw index (HBI). Patients with HBI < 5 were considered to be in clinical remission. Patients who stopped needing steroids at week 24 were defined as being in steroid-free clinical remission. RESULTS: A total of 106 CD patients from eight Israeli centers were included. All patients were previously exposed to at least one biological agent. Our cohort consisted of 65 (61.3%) females. Mean age was 41 ± 14 years with an average disease duration of 12.2 ± 8 years. A total of 96 (90.5%) patients continued treatment throughout week 24. Clinical response was observed in 52% of these patients with mean HBI reduction from 8.34 ± 3.8 to 6.8 ± 4.4 at week 24 (p = 0.001). Clinical remission was achieved in 33 patients (31.1%). Moreover, the number of patients requiring steroid treatment was reduced by 66% at week 24. Out of 106 patients, 11 patients (10.4%) discontinued treatment: 3 due to adverse events (2.8%), 7 due to a lack of response, and 1 who was lost to follow-up. Following 24 weeks of treatment, 15 patients reported minor adverse events. CONCLUSIONS: In a large real-world Israeli cohort of non-naïve-to-biological-treatment CD patients, ustekinumab was effective and safe in induction of clinical remission with a significant reduction in the number of patients requiring steroid treatment.
INTRODUCTION:Ustekinumab is an effective treatment of Crohn's disease (CD). Real-world data addressing the efficacy and safety of ustekinumab are scarce. AIM: Our aim was to assess the safety and efficacy of ustekinumab in a large national patient cohort. METHODS: A prospective multicenter study, in which we followed patients with active CD treated with ustekinumab for 24 weeks. Induction dose was intravenous ranging from 260 to 520 mg, according to body weight, followed by 90 mg doses given subcutaneously every 8 weeks. Clinical response was defined as a reduction of at least 1 severity category, as defined by Harvey-Bradshaw index (HBI). Patients with HBI < 5 were considered to be in clinical remission. Patients who stopped needing steroids at week 24 were defined as being in steroid-free clinical remission. RESULTS: A total of 106 CDpatients from eight Israeli centers were included. All patients were previously exposed to at least one biological agent. Our cohort consisted of 65 (61.3%) females. Mean age was 41 ± 14 years with an average disease duration of 12.2 ± 8 years. A total of 96 (90.5%) patients continued treatment throughout week 24. Clinical response was observed in 52% of these patients with mean HBI reduction from 8.34 ± 3.8 to 6.8 ± 4.4 at week 24 (p = 0.001). Clinical remission was achieved in 33 patients (31.1%). Moreover, the number of patients requiring steroid treatment was reduced by 66% at week 24. Out of 106 patients, 11 patients (10.4%) discontinued treatment: 3 due to adverse events (2.8%), 7 due to a lack of response, and 1 who was lost to follow-up. Following 24 weeks of treatment, 15 patients reported minor adverse events. CONCLUSIONS: In a large real-world Israeli cohort of non-naïve-to-biological-treatment CDpatients, ustekinumab was effective and safe in induction of clinical remission with a significant reduction in the number of patients requiring steroid treatment.
Authors: Stephen B Hanauer; William J Sandborn; Brian G Feagan; Christopher Gasink; Douglas Jacobstein; Bin Zou; Jewel Johanns; Omoniyi J Adedokun; Bruce E Sands; Paul Rutgeerts; Willem J S de Villiers; Jean-Frédéric Colombel; Subrata Ghosh Journal: J Crohns Colitis Date: 2020-01-01 Impact factor: 9.071
Authors: Sam Khorrami; Daniel Ginard; Ignacio Marín-Jiménez; María Chaparro; Mónica Sierra; Mariam Aguas; Beatriz Sicilia; Valle García-Sánchez; Cristina Suarez; Albert Villoria; Carlos Taxonera; Antonio Velasco-Guardado; Javier Martínez-González; Javier P Gisbert Journal: Inflamm Bowel Dis Date: 2016-07 Impact factor: 5.325
Authors: Claire Liefferinckx; Bram Verstockt; Ann Gils; Maja Noman; Catherine Van Kemseke; Elisabeth Macken; Martine De Vos; Wouter Van Moerkercke; Jean-Francois Rahier; Peter Bossuyt; Joris Dutré; Evelien Humblet; Dirk Staessen; Harald Peeters; Philippe Van Hootegem; Edouard Louis; Denis Franchimont; Filip Baert; Séverine Vermeire Journal: J Crohns Colitis Date: 2019-10-28 Impact factor: 9.071
Authors: C Ma; R N Fedorak; G G Kaplan; L A Dieleman; S M Devlin; N Stern; K I Kroeker; C H Seow; Y Leung; K L Novak; B P Halloran; V W Huang; K Wong; P K Blustein; S Ghosh; R Panaccione Journal: Aliment Pharmacol Ther Date: 2017-03-02 Impact factor: 8.171
Authors: William J Sandborn; Christopher Gasink; Long-Long Gao; Marion A Blank; Jewel Johanns; Cynthia Guzzo; Bruce E Sands; Stephen B Hanauer; Stephan Targan; Paul Rutgeerts; Subrata Ghosh; Willem J S de Villiers; Remo Panaccione; Gordon Greenberg; Stefan Schreiber; Simon Lichtiger; Brian G Feagan Journal: N Engl J Med Date: 2012-10-18 Impact factor: 91.245
Authors: U Kopylov; W Afif; A Cohen; A Bitton; G Wild; T Bessissow; J Wyse; T Al-Taweel; A Szilagyi; E Seidman Journal: J Crohns Colitis Date: 2014-07-01 Impact factor: 9.071
Authors: Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts Journal: N Engl J Med Date: 2016-11-17 Impact factor: 91.245
Authors: Anna Viola; Marco Muscianisi; Fabio S Macaluso; Marco Ventimiglia; Maria Cappello; Antonino C Privitera; Antonio Magnano; Dario Pluchino; Giovanni Magrì; Concetta Ferracane; Filippo Mocciaro; Serena Garufi; Enrica Giuffrida; Giuseppe Costantino; Gabriele Fiocco; Mauro Grova; Laura Guida; Angela Alibrandi; Ambrogio Orlando; Walter Fries Journal: JGH Open Date: 2021-02-02
Authors: Gala M Godoy Brewer; George Salem; Muhammad A Afzal; Berkeley N Limketkai; Zadid Haq; Maryam Tajamal; Joanna Melia; Mark Lazarev; Florin M Selaru; Alyssa M Parian Journal: BMJ Open Gastroenterol Date: 2021-12
Authors: Clas-Göran Af Björkesten; Tuire Ilus; Taru Hallinen; Erkki Soini; Anja Eberl; Kalle Hakala; Mikko Heikura; Airi Jussila; Ritva Koskela; Inka Koskinen; Veikko Moilanen; Christian Nielsen; Urpo Nieminen; Heikki Nuutinen; Markku Heikkinen; Ulla-Maija Suhonen; Jyrki Tillonen; Karri Utriainen; Ilkka Vihriälä; Christina Wennerström; Andras Borsi; Riikka Nissinen; Minni R Koivunen; Taina Sipponen Journal: Eur J Gastroenterol Hepatol Date: 2020-12 Impact factor: 2.586